MeiraGTx is advancing its clinical pipeline, with a pivotal Phase 2 data readout for radiation-induced xerostomia expected in mid-2027 and a cash runway extending into the second half of 2028.
The Q3 2026 update confirms the bota-vec MAA dossier is complete with EMA submission planned for December 2026 and the FDA BLA to follow in Q1 2027, ahead of a first commercial launch in late 2027. This de-risks the lead program timeline and points to upcoming regulatory catalysts. No quarterly revenue or loss figures are given, and the milestones were broadly expected, limiting the surprise.
MeiraGTx Holdings reported its third quarter 2026 results, confirming the completion of the MAA dossier for its lead candidate, bota-vec, with an EMA submission planned for December 2026. The company expects to follow this with a full BLA submission to the FDA in the first quarter of 2027, targeting a commercial launch in late 2027.
The European MAA dossier is complete and is intended to be submitted to the EMA in December 2026, with the full BLA to the FDA expected to follow in the first quarter of 2027.
The pivotal Phase 2 AQUAx2 study for radiation-induced xerostomia has a 12-month pivotal data readout expected in mid-2027, which if positive could support a BLA submission by the end of 2027.